NCT07003542View on ClinicalTrials.gov

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 8, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
GlioblastomaBrain Tumor
Interventions
DRUG

Sitagliptin

"Sitagliptin will be self-administered orally by participants.~Dose level - sitagliptin~* 1 100 mg daily~* -1 50 mg daily~* -2 25 mg daily"

Trial Locations (1)

44195

RECRUITING

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT07003542 - A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas | Biotech Hunter | Biotech Hunter